Interleukin-1 Receptor Antagonist Enhances Islet Engraftment Without Impacting Serum Levels of Nitrite or Osteopontin

Transplantation Proceedings

Volumn 41, Issue 5, 2009, Pages 1781-1785

  Hsu, B R ^a   Fu, S H ^a   Hsu, S ^a   Chen, S T ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; COMPLEMENTARY DNA; GLUCOSE; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NITRITE; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; EXPERIMENTAL MOUSE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; STREPTOZOCIN DIABETES;

ADENOVIRIDAE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DNA, COMPLEMENTARY; INSULIN; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; ISLETS OF LANGERHANS TRANSPLANTATION; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; NITRITES; OSTEOPONTIN;

EID: 67249153608     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.10.099     Document Type: Article

References (18)

1. Arafat H.A., Katakam A.K., Chipitsyna G., et al. Osteopontin protects the islets and β-cells from interleukin-1β-mediated cytotoxicity through negative feedback regulation of nitric oxide. Endocrinology 148 (2007) 575
2. Biarnes M., Montolio M., Nacher V., et al. β-Cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 51 (2002) 66
3. Dionne K.E., Colton C.K., and Yarmush M.L. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 42 (1993) 12
4. Eizirik D.L., Tracey D.E., Bendtzen K., et al. An interleukin-1 receptor antagonist protein protects insulin-producing β-cells against suppressive effects of interleukin-1. Diabetologia 34 (1991) 445
5. Emamaullee J., and Shapiro A.M. Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant 16 (2007) 1
6. Granowitz E.V., Porat R., Mier J.W., et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4 (1992) 353
7. Gysemans C., Stoffels K., Giulietti A., et al. Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents. Diabetologia 46 (2003) 1115
8. Hsu B.R.S., Chen S.T., and Fu S.H. Enhancing engraftment of islets using perioperative sodium 4-phenylbutyrate. Int Immunopharmacol 6 (2006) 1952
9. Juang J.H., Hsu B.R.S., Kuo C.H., et al. Beneficial effects of hyperbaric oxygen therapy on islet transplantation. Cell Transplant 11 (2002) 95
10. Katakam A.K., Chipitsyna G., Gong Q., et al. Streptozotocin (STZ) mediates acute upregulation of serum and pancreatic osteopontin (OPN): a novel islet-protective effect of OPN through inhibition of STZ-induced nitric oxide production. J Endocrinol 187 (2005) 237
11. Kaufman D.B., Gores P.F., Field M.J., et al. Effect of 15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass. Diabetes 43 (1994) 778
12. Merino J.F., Nacher V., Raurell M., et al. Improved outcome of islet transplantation in insulin-treated diabetic mice: effects on beta-cell mass and function. Diabetologia 40 (1997) 1004
13. Montana E., Bonner-Weir S., and Weir G.C. Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice. J Clin Invest 91 (1993) 780
14. Montolio M., Biarnes M., Tellez N., et al. Interleukin-1β and inducible form of nitric oxide synthase expression in early syngeneic islet transplantation. J Endocrinol 192 (2007) 169
15. Montolio M., Tellez N., Soler J., et al. Role of blood glucose in cytokine gene expression in early syngeneic islet transplantation. Cell Transplant 16 (2007) 517
16. Sandberg J.O., Eizirik D.L., Sandler S., et al. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes 42 (1993) 1845
17. Tellez N., Montolio M., Estilles E., et al. Adenoviral overproduction of interleukin-1 receptor antagonist increases beta cell replication and mass in syngeneically transplanted islets, and improves metabolic outcome. Diabetologia 50 (2007) 602
18. Zumsteg U., Reimers J.I., Pociot F., et al. Differential interleukin-1 receptor antagonism on pancreatic beta and alpha cells. Studies in rodent and human islets and in normal rats. Diabetologia 36 (1993) 759